Therapeutic targeting of trained immunity
- 9 April 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 18 (7), 553-566
- https://doi.org/10.1038/s41573-019-0025-4
Abstract
Immunotherapy is revolutionizing the treatment of diseases in which dysregulated immune responses have an important role. However, most of the immunotherapy strategies currently being developed engage the adaptive immune system. In the past decade, both myeloid (monocytes, macrophages and dendritic cells) and lymphoid (natural killer cells and innate lymphoid cells) cell populations of the innate immune system have been shown to display long-term changes in their functional programme through metabolic and epigenetic programming. Such reprogramming causes these cells to be either hyperresponsive or hyporesponsive, resulting in a changed immune response to secondary stimuli. This de facto innate immune memory, which has been termed ‘trained immunity’, provides a powerful ‘targeting framework’ to regulate the delicate balance of immune homeostasis, priming, training and tolerance. In this Opinion article, we set out our vision of how to target innate immune cells and regulate trained immunity to achieve long-term therapeutic benefits in a range of immune-related diseases. These include conditions characterized by excessive trained immunity, such as inflammatory and autoimmune disorders, allergies and cardiovascular disease and conditions driven by defective trained immunity, such as cancer and certain infections.Keywords
This publication has 156 references indexed in Scilit:
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Perspectives and opportunities for nanomedicine in the management of atherosclerosisNature Reviews Drug Discovery, 2011
- Therapeutic siRNA silencing in inflammatory monocytes in miceNature Biotechnology, 2011
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Nanoparticulate Assemblies of Amphiphiles and Diagnostically Active Materials for Multimodality ImagingAccounts of Chemical Research, 2009
- Adaptive immune features of natural killer cellsNature, 2009
- Cancer-related inflammationNature, 2008
- The Hospital for the Ruptured and Crippled: William Bradley Coley, Third Surgeon-in-Chief 1925–1933HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2008